A Study to Assess New Formulations of TEV-56286
- Study Title
- An Open-Label, Randomized, Crossover Study to Assess the Comparative Bioavailability of New TEV-56286 Formulations Compared to a Reference TEV-56286 Capsule Formulation Following Single-Dose Administration in Healthy Participants
- Teva Identifier
- TV56286-BA-10218
- ClinicalTrials.gov Identifier
- NCT06911567
- Study Status
- Recruiting
- Trial Condition(s)
- Healthy Participants
- Interventions
- Drug: TEV-56286 Test | Drug: TEV-56286 Reference
- Study Description
- The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 years to 60 Years
- Trial Duration
- March 10, 2025 - May 29, 2025
- Phase
- Phase 1
